Goldman Sachs
IMRX icon

Goldman Sachs’s Immuneering IMRX Stock Holding History

Goldman Sachs’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.73M Buy
327,655
+8,846
+3% +$45.3K ﹤0.01% 4665
2025
Q4 		$2.1M Buy
+318,809
New +$2.05M ﹤0.01% 4543
2024
Q3 		– Sell
-741,548
Closed -$949K – 5958
2024
Q2 		$949K Buy
741,548
+287,315
+63% +$472K ﹤0.01% 4445
2024
Q1 		$1.31M Sell
454,233
-2,826
-0.6% -$15.8K ﹤0.01% 4160
2023
Q4 		$3.36M Sell
457,059
-25,871
-5% -$172K ﹤0.01% 3503
2023
Q3 		$3.71M Sell
482,930
-5,933
-1% -$54.5K ﹤0.01% 3256
2023
Q2 		$4.96M Buy
488,863
+462,652
+1,765% +$4.45M ﹤0.01% 3116
2023
Q1 		$255K Buy
26,211
+15,934
+155% +$90.5K ﹤0.01% 5190
2022
Q4 		$49.8K Sell
10,277
-1,551
-13% -$13.7K ﹤0.01% 5598
2022
Q3 		$169K Sell
11,828
-6,756
-36% -$53.6K ﹤0.01% 5537
2022
Q2 		$101K Buy
18,584
+3,528
+23% +$18.8K ﹤0.01% 5863
2022
Q1 		$97K Buy
15,056
+1,894
+14% +$18.2K ﹤0.01% 6118
2021
Q4 		$213K Buy
+13,162
New +$320K ﹤0.01% 5865

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's IMRX Position: Q1 2026 in Review

Goldman Sachs increased its Immuneering (IMRX) stake by 2.8% in Q1 2026, buying an estimated $45.3K and bringing the position to 327,655 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #4665.

Goldman Sachs first reported a position in IMRX in Q4 2021 and has held it in 13 quarters since. The position peaked at $4.96M in Q2 2023. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Goldman Sachs held 327,655 shares of Immuneering worth $1.73M as of Q1 2026.
  • Goldman Sachs bought 8,846 Immuneering shares in Q1 2026, an estimated $45.3K.
  • Immuneering made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4665 holding.
  • Goldman Sachs first reported a position in Immuneering in Q4 2021 and has held it in 13 quarters since.
  • Goldman Sachs's Immuneering position peaked at $4.96M in Q2 2023.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.